These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 24863058)

  • 21. Blockade of sodium-glucose cotransporter 2 suppresses high glucose-induced angiotensinogen augmentation in renal proximal tubular cells.
    Satou R; Cypress MW; Woods TC; Katsurada A; Dugas CM; Fonseca VA; Navar LG
    Am J Physiol Renal Physiol; 2020 Jan; 318(1):F67-F75. PubMed ID: 31682172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inflammation in Renal Diseases: New and Old Players.
    Andrade-Oliveira V; Foresto-Neto O; Watanabe IKM; Zatz R; Câmara NOS
    Front Pharmacol; 2019; 10():1192. PubMed ID: 31649546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Learning Physiology From Inherited Kidney Disorders.
    van der Wijst J; Belge H; Bindels RJM; Devuyst O
    Physiol Rev; 2019 Jul; 99(3):1575-1653. PubMed ID: 31215303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
    Perkovic V; Jardine MJ; Neal B; Bompoint S; Heerspink HJL; Charytan DM; Edwards R; Agarwal R; Bakris G; Bull S; Cannon CP; Capuano G; Chu PL; de Zeeuw D; Greene T; Levin A; Pollock C; Wheeler DC; Yavin Y; Zhang H; Zinman B; Meininger G; Brenner BM; Mahaffey KW;
    N Engl J Med; 2019 Jun; 380(24):2295-2306. PubMed ID: 30990260
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Dapagliflozin on Endothelial Function, Renal Injury Markers, and Glycemic Control in Drug-Naïve Patients with Type 2 Diabetes Mellitus.
    Kong SH; Koo BK; Moon MK
    Diabetes Metab J; 2019 Oct; 43(5):711-717. PubMed ID: 30968615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dipeptidyl Peptidase 4 Inhibition Ameliorates Chronic Kidney Disease in a Model of Salt-Dependent Hypertension.
    Cappetta D; Ciuffreda LP; Cozzolino A; Esposito G; Scavone C; Sapio L; Naviglio S; D'Amario D; Crea F; Rossi F; Berrino L; De Angelis A; Urbanek K
    Oxid Med Cell Longev; 2019; 2019():8912768. PubMed ID: 30774748
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High Salt Enhances Reactive Oxygen Species and Angiotensin II Contractions of Glomerular Afferent Arterioles From Mice With Reduced Renal Mass.
    Li L; Lai EY; Luo Z; Solis G; Mendonca M; Griendling KK; Wellstein A; Welch WJ; Wilcox CS
    Hypertension; 2018 Nov; 72(5):1208-1216. PubMed ID: 30354808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.
    Thomas MC; Cherney DZI
    Diabetologia; 2018 Oct; 61(10):2098-2107. PubMed ID: 30132034
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy.
    Cassis P; Locatelli M; Cerullo D; Corna D; Buelli S; Zanchi C; Villa S; Morigi M; Remuzzi G; Benigni A; Zoja C
    JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice.
    Zhang Y; Nakano D; Guan Y; Hitomi H; Uemura A; Masaki T; Kobara H; Sugaya T; Nishiyama A
    Kidney Int; 2018 Sep; 94(3):524-535. PubMed ID: 30045814
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic rats.
    Jaikumkao K; Pongchaidecha A; Chueakula N; Thongnak LO; Wanchai K; Chatsudthipong V; Chattipakorn N; Lungkaphin A
    Diabetes Obes Metab; 2018 Nov; 20(11):2617-2626. PubMed ID: 29923295
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High salt diet induces metabolic alterations in multiple biological processes of Dahl salt-sensitive rats.
    Wang Y; Liu X; Zhang C; Wang Z
    J Nutr Biochem; 2018 Jun; 56():133-141. PubMed ID: 29567533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study.
    Solini A; Giannini L; Seghieri M; Vitolo E; Taddei S; Ghiadoni L; Bruno RM
    Cardiovasc Diabetol; 2017 Oct; 16(1):138. PubMed ID: 29061124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure.
    Packer M
    Circulation; 2017 Oct; 136(16):1548-1559. PubMed ID: 29038209
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesis.
    Gaspari T; Spizzo I; Liu H; Hu Y; Simpson RW; Widdop RE; Dear AE
    Diab Vasc Dis Res; 2018 Jan; 15(1):64-73. PubMed ID: 28976221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.
    Cherney DZI; Cooper ME; Tikkanen I; Pfarr E; Johansen OE; Woerle HJ; Broedl UC; Lund SS
    Kidney Int; 2018 Jan; 93(1):231-244. PubMed ID: 28860019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Involvement of Cytokines in the Pathogenesis of Salt and Water Imbalance in Congestive Heart Failure.
    Azzam ZS; Kinaneh S; Bahouth F; Ismael-Badarneh R; Khoury E; Abassi Z
    Front Immunol; 2017; 8():716. PubMed ID: 28674538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
    Neal B; Perkovic V; Mahaffey KW; de Zeeuw D; Fulcher G; Erondu N; Shaw W; Law G; Desai M; Matthews DR;
    N Engl J Med; 2017 Aug; 377(7):644-657. PubMed ID: 28605608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sodium glucose transporter-2 inhibition has no renoprotective effects on non-diabetic chronic kidney disease.
    Ma Q; Steiger S; Anders HJ
    Physiol Rep; 2017 Apr; 5(7):. PubMed ID: 28364032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of ranolazine in a model of doxorubicin-induced left ventricle diastolic dysfunction.
    Cappetta D; Esposito G; Coppini R; Piegari E; Russo R; Ciuffreda LP; Rivellino A; Santini L; Rafaniello C; Scavone C; Rossi F; Berrino L; Urbanek K; De Angelis A
    Br J Pharmacol; 2017 Nov; 174(21):3696-3712. PubMed ID: 28320043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.